Lindbrook Capital, LLC Apellis Pharmaceuticals, Inc. Transaction History
Lindbrook Capital, LLC
- $1.06 Billion
- Q1 2025
A detailed history of Lindbrook Capital, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 516 shares of APLS stock, worth $8,715. This represents 0.0% of its overall portfolio holdings.
Number of Shares
516
Previous 673
23.33%
Holding current value
$8,715
Previous $21,000
47.62%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$208 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$206 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$201 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$171 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$163 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $1.86B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...